PMGC Holdings Inc(ELAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:31 PM ET (Korea 10/31 05:31)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1815.13 | Insider Own | - | Shs Outstand | 0.8M | Perf Week | -3.91% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -19.38% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 3.28% | Short Float | 2.29% | Perf Quarter | -71.49% |
| Income | -0.01B | P/S | 0.82 | EPS this Y | - | Inst Trans | 310.32% | Short Ratio | 0.44 | Perf Half Y | -89.64% |
| Sales | 0.00B | P/B | 0.1 | EPS next 5Y | - | ROA | -59.06% | Short Interest | 0.02M | Perf YTD | -99.27% |
| Book/sh | 27.2 | P/C | 0.11 | EPS past 3/5Y | 74.26% 15.55% | ROE | -105.22% | 52W High | -99.83% ($1491.82) | Perf Year | -99.82% |
| Cash/sh | 23.18 | P/FCF | - | Sales past 3/5Y | -8.34% - | ROIC | -63.6% | 52W Low | 3.2% ($2.52) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.47% | Gross Margin | 10.31% | Volatility(W/M) | 8.67% 6.81% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -0.95 | Sales Y/Y TTM | - | Oper. Margin | -477.02% | ATR (14) | 0.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | 98.41% | Profit Margin | -522.97% | RSI (14) | 25.69 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.36 | Sales Q/Q | - | SMA20 | -9.5% ($2.87) | Beta | -0.27 | Target Price | - |
| Payout | - | Debt/Eq | 0.85 | Earnings | - | SMA50 | -35.79% ($4.05) | Rel Volume | 0.18 | Prev Close | $2.64 |
| Employees | 34 | LT Debt/Eq | 0.27 | EPS/Sales Surpr. | - | SMA200 | -92.69% ($35.57) | Avg Volume(3M) | 0.04M | Price | $2.6 |
| IPO | 2023/11/21 | Option/Short | No/Yes | Trades | 223 | Volume | 7,501 | Change | -1.52% |
🧬 (PMGC Holdings) is a US small-cap diversified holding company spanning biotech, research, finance, and precision manufacturing. Its core subsidiary, Northstrive Biosciences, is developing EL-22, an oral probiotic designed to prevent muscle loss during GLP-1 obesity treatment, while the company as a whole is simultaneously pursuing the expansion of its business portfolio through mergers and acquisitions.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 18% of its average volume.
ELAB has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $82. Peers typically go for $1,010.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.3%.
Tap to view numbers
It ranks #575 of 597 in the industry
Based on market cap of $2M.
FAQ
What kind of company is ELAB?
ELAB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ELAB?
The market cap of ELAB is approximately $2M, ranking 5,793 within its sector.
What is the 52-week high and low for ELAB?
ELAB has recorded a 52-week high of $1491.82 and a low of $2.52.
